Navigation Links
New class of drug targets skin cancer
Date:5/7/2013

7 May, 2013 -- Sydney, Australia:

A new class of drug targeting skin cancer's genetic material has been successfully tested in humans for the first time, opening the way to new treatments for a range of conditions from skin cancers to eye diseases.

The research involves the drug Dz13, a targeted molecular therapy, which was developed at the University of New South Wales (UNSW) and has now been found to be safe in a clinical trial of patients with the common skin cancer, basal-cell carcinoma.

"This is the first report of a drug of this type to be used in humans," says UNSW Medicine's Professor Levon Khachigian, who has been developing the DNAzyme technology for 10 years.

"It's a smart drug, which targets a bad protein that controls tumour growth and spread," says Professor Khachigian, the Director of the UNSW Centre for Vascular Research. The collaborative trial was conducted by researchers from UNSW, the University of Sydney and Royal Prince Alfred Hospital.

The findings have been published today in the prestigious journal The Lancet.

"Even though we were only testing for safety, there were unexpected positive effects," says Professor Khachigian.

"The drug knocked down levels of this bad protein and the tumours shrunk in the majority of patients."

The researchers hope subsequent trials will prove that larger doses of the drug over a longer time period will be more effective.

"Targeted molecular therapy like this might also offer novel, effective, and less invasive therapeutic options for basal-cell carcinoma," says Professor Gary Halliday, from the University of Sydney, who is one of the co-authors of the study.

If the next stages of the clinical trials in basal-cell carcinoma are successful, the researchers hope that within three years, the drug could be used as a treatment for these cancers, reducing scarring and the costs and inconvenience associated with surgery.

Basal-cell carcinoma is the most common cancer among fair-skinned people worldwide with Australia having the highest incidence.

"This may be a 'one-size fits all' therapy, because it targets a master regulator gene called c-Jun which appears to be involved in a range of diseases," says Professor Khachigian, who predicts that melanoma and eye diseases including macular degeneration and diabetic retinopathy are the likely future targets for research.

A phase one trial in skin melanoma is expected to begin in a month.


'/>"/>

Contact: Susi Hamilton
susi.hamilton@unsw.edu.au
61-422-934-024
University of New South Wales
Source:Eurekalert

Related medicine news :

1. Parker Waichman LLP Files Class Action Lawsuit on Behalf of Consumers Who’ve Purchased Azek Decking
2. Studio Pulse Announces New Website Making It Easier for Clients to Learn About Their Program and Sign Up for Classes Online
3. Special Learning, Inc. to Bring World-Class Education and Treatment Programs for Special Needs to the Philippines
4. Tools4ever Creates and Launches New Connector between its User Management Resource Administrator and the enterprise-class email solution, Zimbra
5. Celebrate National CPR/AED Week in June by Organizing an American Heart Association CPR & First-Aid Certification Class with Safety Training Seminars
6. San Jose CPR Certification Now Sells AEDs (Automated External Defibrillators) and Teaches CPR/AED Certification Training Classes in San Jose, CA
7. Flavor Your Life Releases Report on Extra Virgin Olive Oil Classification
8. Altman Fitness’ Eden Twin Cities Boot Camp Is Giving Away Classes
9. Class Action Imprelis Lawsuit Filed on Behalf of Multiple Property Owners Who Allege Imprelis Use Caused Extensive Tree Damage and Death, Reports Wright & Schulte
10. Hanley Center Foundation Takes Golf Classic to The Medalist
11. Enterprise Rent-A-Car 8th Annual Golf Classic to Be Held on Thursday, May 9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, ... http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of drug and device marketing and ... compliance with FDA rules. , The FDA has issued two draft guidances that ...
(Date:9/21/2017)... ... September 21, 2017 , ... In addition to sticking with ... more holistic approach and use natural alternatives for all house cleaning products, disinfectants, ... USDA guaranteeing that, the new line of essential oils, are all 100% organic ...
(Date:9/21/2017)... ... September 21, 2017 , ... Japanese Zen artist couple, ... Revolution” on 6th, 7th and 8th October at Miranda Kuo Gallery on Lower East ... pieces, such as Zen Kodo mat. Wanderlust , one of the largest US ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... serving communities in northern Alabama and Georgia, is embarking on an extended charity ... utilizing modern early detection methods. , US Breast Cancer statistics show that ...
(Date:9/20/2017)... ... September 20, 2017 , ... Collins Concrete ... for clients that rely on safety and cleanliness. This unique flooring system uses ... has been used for centuries for its antimicrobial properties. Unlike antibiotics, which kill ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform ... published the first annual edition of its Global CSR Risk and Performance ... evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data ... ... ...
(Date:9/9/2017)... Sept. 9, 2017  Eli Lilly and Company (NYSE: ... secondary endpoint data for lasmiditan, an investigational, oral, first-in-class ... statistically significant improvements compared to placebo in the Phase ... at the 18th Congress of the International Headache Society ... "The data presented today demonstrate lasmiditan,s potential to reduce ...
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Medicine Technology: